Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal
Authors:
- 20 August 2012
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 18 (11) , 1647-1649
Abstract
We report the case of a woman with multiple sclerosis who developed a severe neurological condition following natalizumab (NZB) withdrawal and soon after fingolimod (FTY) initiation. FTY was started 3.5 months after a two-year NZB treatment. Fifteen days later, she suffered partial repetitive seizures followed by a tonicoclonic seizure. This was associated with attention difficulties and an increased asthenia. Brain MRI follow-up disclosed large demyelinating active lesions in favour of disease reactivation. This case suggests that FTY introduction may occur less than three months after NZB withdrawal.Keywords
This publication has 9 references indexed in Scilit:
- Severe multiple sclerosis relapse under fingolimod therapy: Incident or coincidence?Neurology, 2012
- Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorderMultiple Sclerosis Journal, 2011
- Disease activity return during natalizumab treatment interruption in patients with multiple sclerosisNeurology, 2011
- Interruption of natalizumab therapy for multiple sclerosisNeurology, 2011
- Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab TherapyArchives of Neurology, 2011
- Considerations on discontinuing natalizumab for the treatment of multiple sclerosisAnnals of Neurology, 2010
- Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapyNeurology, 2009
- POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTSNeurology, 2008
- A Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2003